 - IND Expands Potential Indications for CRV431 Beyond NASH to Include COVID-19 - - CRV431 Poised to Move Directly into Phase 2 Clinical Study for COVID-19 - - Company May Seek Partnerships for COVID-19 Drug Development - EDISON, NJ ACCESSWIRE December 22, 2020 Hepion Pharmaceuticals, Inc. NASDAQ:HEPAHepion, a clinical-stage biopharmaceutical company focused on Artificial Intelligence AI-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis NASH and liver disease, today announced that the U.S. Food and Drug Administration FDA has accepted its investigational new drug IND application for CRV431, a novel cyclophilin inhibitor for the treatment of COVID-19. On July 7, 2020, Hepion announced a potential two-pronged strategy to treat COVID-19. 